ArticleFrontiers in medicine2026
Documented risk-based antithrombotic management and 30-day outcomes after endoscopic hemostasis for non-variceal upper gastrointestinal bleeding: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate whether documented adherence to a prespecified risk-based antithrombotic management framework was associated with 30-day rebleeding, thromboembolism, and net adverse clinical events (NACE) after therapeutic endoscopy for non-variceal upper gastrointestinal bleeding (NVUGIB). Methods: This single-center retrospective cohort included 150 unique index admissions from January 2021 through December 2025. Documented strategy adherence was coded in 100 patients and non-adherence in 50. Rebleeding was evaluated only after successful initial hemostasis ( Results: Thirty-day rebleeding occurred in 13/141 patients (9.2%), thromboembolism in 16/150 (10.7%), death in 6/150 (4.0%), and NACE in 29/150 (19.3%). Rebleeding was observed in 5/96 adherent patients (5.2%) and 8/45 non-adherent patients (17.8%; Fisher Conclusion: Documented adherence to a risk-based management framework was associated with fewer 30-day adverse events. Because exposure classification depended on clinical documentation, residual confounding and misclassification remain likely, and the large adjusted effects should not be interpreted causally. Individualized multidisciplinary assessment appears more important than any single predefined resumption threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.